Modality
Fusion Protein
MOA
IL-23i
Target
CFTR
Pathway
Cell Cycle
AsthmaMyelofibrosis
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Dec 2026
Phase 1Current
NCT04104806
845 pts·Myelofibrosis
2017-01→2026-12·Completed
NCT07646684
575 pts·Asthma
2023-12→2026-07·Active
1,420 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-053mo awayInterim· Asthma
2026-12-048mo awayInterim· Myelofibrosis
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2026-07-05 · 3mo away
Asthma
Interim
2026-12-04 · 8mo away
Myelofibrosis
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04104806 | Phase 1 | Myelofibrosis | Completed | 845 | EFS |
| NCT07646684 | Phase 1 | Asthma | Active | 575 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 |